Why Every Drug Test Needs MRO Review, Not Just the Positives

In the world of workplace drug testing, consistency is compliance.

Yet many employers still follow an outdated practice: sending only laboratory-confirmed positive results to the Medical Review Officer (MRO) while allowing negative results to bypass medical review altogether.

It may seem efficient. It may even feel cost-effective.

But from a non-DOT drug testing compliance, DOT compliance, and C/TPA best practices standpoint, selective MRO review creates unnecessary risk.

If you are serious about protecting your company, your program, and your documentation trail, every test deserves the same level of scrutiny.

Here is why.

1. Chain of Custody Errors Don’t Care About the Result

A negative test with a flawed Chain of Custody Form (CCF) is just as vulnerable as a positive result if challenged.

• Collection errors.
• Incomplete CCF documentation.
• Specimen labeling issues.
• Temperature discrepancies.
• Shipping or handling mistakes.

These issues happen regardless of the lab outcome.

In both DOT compliance programs and non-DOT drug testing compliance environments, procedural integrity is foundational. If you only review positives, you are essentially auditing your documentation only when someone fails.

That is not consistency. That is reactive oversight.

Comprehensive MRO review ensures every CCF meets the same standard. It creates uniform quality control across the entire testing program, which is a core component of C/TPA best practices.

2. Most Disputes Are About Process, Not the Lab Result

Here is something many employers learn the hard way: workplace disputes often revolve around procedure, not chemistry.

Common issues include:

• Wrong test panel ordered.
• Incorrect reason for test documented.
• Collector errors.
• Administrative mismatches.
• Policy inconsistencies.

These occur in negative results just as often as positives.

In non-DOT programs, where policies vary widely, consistency becomes even more critical. Without full MRO review, procedural errors in negative tests can quietly accumulate. Then, during an unemployment hearing, grievance, or litigation, patterns begin to surface.

Full-panel MRO oversight acts as a structured compliance checkpoint. It identifies gaps early and allows corrections before they become legal arguments.

And in compliance, prevention is always less expensive than defense.

3. Fairness Must Be Demonstrable — Not Assumed

In today’s workplace environment, perception matters.

If only positive results receive physician review, opposing counsel can argue selective enforcement. In cases involving discrimination claims, retaliation allegations, or inconsistent policy implementation, that perception can be damaging.

Applying MRO oversight to every test demonstrates:

• Equal treatment of all donors.
• Uniform application of policy.
• Standardized medical evaluation.
• Objective decision-making.

From a DOT compliance perspective, uniformity is already expected. From a non-DOT drug testing compliance standpoint, it is simply smart risk management.

Consistency strengthens credibility.

4. A Defensible Program Requires a Defensible Paper Trail

Every employer hopes they never need to defend their testing program.

But if you do, documentation will matter more than anything else.

A testing program is far easier to defend when:

• Every result follows the same review pathway.
• Every CCF is evaluated.
• Every decision reflects standardized oversight.
• Every file contains consistent documentation.

Whether facing an unemployment hearing, internal dispute, regulatory inquiry, or legal challenge, you want to be able to state confidently:

“Every single test, without exception, goes through the same medical review process.”

That statement aligns with C/TPA best practices and strengthens both DOT compliance and non-DOT program defensibility.

Selective review creates variability. Variability creates vulnerability.

The Hidden Risk of Reviewing Only Positives

Limiting MRO involvement to confirmed positives may reduce administrative touchpoints in the short term. But it creates long-term exposure:

• Inconsistent documentation
• Unreviewed procedural errors
• Perceived unfair treatment
• Weak compliance defenses

A comprehensive MRO review model closes those gaps.

• It enhances credibility.
• It strengthens internal controls.
• It supports audit readiness.
• It protects employers, C/TPAs, and donors alike.

In other words, it keeps your compliance program intact — and your legal team bored.

Audit Before You’re Audited

In both DOT compliance and non-DOT drug testing compliance programs, the strongest systems are proactive, not reactive.

If your current process sends only positive results to the MRO, it is time to reassess.

Ask yourself:

• Are we applying consistent oversight to every donor?
• Would our documentation hold up under cross-examination?
• Are we following true C/TPA best practices, or just industry habits?

Compliance is not about convenience. It is about doing what is defensible.

And in workplace drug testing, defensibility comes from consistency.

Every test. Every time.